Sanofi (NYSE:SNY) announced today that it entered into a collaboration with Aetion to integrate its Darwin data platform with the Aetion Evidence platform to try and advance the efficiency of real-world evidence.
The collaboration between the two companies will set out to facilitate regulatory-grade studies with deep transparency while opening access to new real-world data, according to a news release.
Sanofi’s Darwin is designed to compile and analyze de-identified data, while the Aeition Evidence platform analyzes real-world data to uncover answers about the effectiveness, safety and value of drugs. The combination of the two could elevate the companies’ analytics capabilities and offer new opportunities for the development and application of medical treatments.
The companies added that their collaboration is an attempt to make a difference in real-world evidence after the FDA recently prioritized efforts to incorporate the concept as a companion to clinical trial data, aiding in regulatory decision making. The FDA is set to release its draft guidance on real-world evidence before the end of 2020.
“Today marks another important step in Sanofi’s digital transformation,” Sanofi global head of medical evidence generation Dr. Bernard Hamelin said in the release. “By integrating these platforms, we strive to make faster, more informed decisions with the potential to lead to first-in-class and best-in-class treatments that could change the practice of medicine.”
“Our work with Sanofi further validates the value and potential for real-world evidence in drug development,” added Aetion CEO Carolyn Magill. “Our companies share a common goal of using the best available data to get the right treatment to the right patient as quickly and efficiently as possible.”